瑞普生物：生物制品13%税率政策短期实际税负将有所上升

Core Viewpoint - The company, Reap Bio, addressed investor concerns regarding the impact of the tax rate increase on biological products from 3% to 13% starting January 1, 2026, stating that it will not affect the 2025 financial results but will lead to a short-term increase in actual tax burden in 2026 [1]. Summary by Categories Financial Impact - The company indicated that the new 13% tax rate will not influence the operating results for 2025, but there will be a short-term increase in tax burden once implemented in 2026 [1]. Strategic Response - Reap Bio plans to mitigate the impact of the tax rate adjustment through optimizing product pricing and structure, as well as improving supplier and procurement management [1]. Compliance and Value Creation - The company emphasized its commitment to strict tax compliance and effective management practices to create value for the company and its shareholders [1].